Influence of microcrystal formulation on in vivo absorption of celecoxib in rats

AAPS PharmSciTech

Volumn 14, Issue 2, 2013, Pages 719-726

  Nasr, Mohamed ^a  

^a Ein Helwan   (Egypt)

Author keywords

celecoxib; dissolution; in vivo absorption; microcrystals; particle size

Indexed keywords

ANIONIC SURFACTANT; CELECOXIB; IONIC SURFACTANT; POLYMER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROMORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 2 INHIBITORS; INTESTINAL ABSORPTION; MALE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDER DIFFRACTION; PYRAZOLES; RATS; RATS, WISTAR; SOLUBILITY; SULFONAMIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84879111402     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9957-x     Document Type: Article

References (31)

1. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225-42.
2. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3-12.
3. Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J Control Release. 2009;134:62-70.
4. Reddy MN, Rehana T, Ramakrishna S, Chowdary KPR, Diwan PV. Β cyclodextrin complexes of celecoxib: molecular-modeling characterization, and dissolution studies. AAPS PharmSci. 2004;6(1):1-9.
5. Orienti I, Bigucci F, Luppi B, Cerchiara T, Zuccari G, Giunchedi P, et al. Polyvinylalcohol substituted with triethyleneglycolmonoethyl ether as a new material for preparation of solid dispersion of hydrophobic drugs. Eur J Pharm Biopharm. 2002;54:229-33.
6. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297:638-45.
7. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm. 2009;73:107-14.
8. Dressmann JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water soluble drugs. Eur J Pharm Sci. 2000;11:73-80.
9. Sarkari M, Brown J, Chen X, Swinnea S, William RO, Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm. 2002;243:17-31.
10. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;5916:31-44.
11. Rasenack N, Steckel H, Müller BW. Preparation of microcrystals by in situ micronization. Powder Technol. 2004;143-144:291-6.
12. Rasenack N, Müller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res. 2002;19:1894-900.
13. Kim ST, Kwon JH, Lee JJ, Kim CW. Microcrystallization of indomethacin using a pH-shift method. Int J Pharm. 2003;263:141-50.
14. Williams 3rd RO, Brown J, Liu J. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm Dev Technol. 1999;4(2):167-79.
15. Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF. Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm. 2009;374(1-2):106-13.
16. Huang QP, Wang JX, Chen GZ, Shen ZG, Chen JF, Yun J. Micronization of gemfibrozil by reactive precipitation process. Int J Pharm. 2008;360:58-64.
17. Gupta VR, Mutalik S, Patel MM, Jani GK. Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties. Acta Pharma. 2007;57:173-84.
18. Dolenc A, Kristl J, Baumgartner S, Planinsek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376:204-12.
19. Margulis-Goshen K, Kesselman E, Danino D, Magdassi S. Formation of celecoxib nanoparticles from volatile microemulsions. Int J Pharm. 2010;393:230-7.
20. Rasenack N, Hartenhauer H, Müller BW. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm. 2003;254:137-45.
21. Liu Y, Sun C, Haob Y, Jiang T, Zheng L, Wang S. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci. 2010;13(4):589-606.
22. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF kappa B. FASEB J. 2001;15(9):1622-4.
23. Park MS, Shim WS, Yim SV, Lee KT. Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. J Chromatogr B Anal Technol Biomed Life Sci. 2012;902:137-41.
24. U.S. Food and Drug Administration. Title 21 Code of Federal Regulations (CFR), Part 320.1. Washington, DC: Office of Federal Register, National Archives and Records Administration, U.S. Government Printing Office; 2010.
25. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, et al. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nano-precipitation method without surfactants. Int J Pharm. 2006;323:153-60.
26. Chawla G, Gupta P, Thilagavathi R. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci. 2003;20:305-17.
27. Varshosaz J, Talari R, Mostafavi SA, Nokhodchi A. Dissolution enhancement of gliclazide using in situ micronization by solvent change method. Powder Technol. 2008;187:222-30.
28. Zhong J, Shen Z, Yang Y, Chen J. Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment. Int J Pharm. 2005;301:286-93.
29. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;28:48-9.
30. Li XS, Wang JX, Shen ZG, Zhang PY, Chen JF, Yun J. Preparation of uniform prednisolone microcrystals by a controlled microprecipitation method. Int J Pharm. 2007;342:26-32.
31. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19:930-4.